Integrated Analysis of Microarray Data of Atherosclerotic Plaques: Modulation of the Ubiquitin-Proteasome System
PLOS ONE
Authors: Wang, Zhe; Guo, Dong; Yang, Bin; Wang, Jian; Wang, Rong; Wang, Xiaowei; Zhang, Qunye
Abstract
Atherosclerosis is a typical complex multi-factorial disease and many molecules at different levels and pathways were involved in its development. Some studies have investigated the dysregulation in atherosclerosis at mRNA, miRNA or DNA methylation level, respectively. However, to our knowledge, the studies that integrated these data and revealed the abnormal networks of atherosclerosis have not been reported. Using microarray technology, we analyzed the omics data in atherosclerosis at mRNA, miRNA and DNA methylation levels. Our results demonstrated that the global DNA methylation and expression of miRNA/mRNA were significantly decreased in atherosclerotic plaque than in normal vascular tissue. The interaction network constructed using the integrative data revealed many genes, cellular processes and signaling pathways which were widely considered to play crucial roles in atherosclerosis and also revealed some genes, miRNAs or signaling pathways which have not been investigated in atherosclerosis until now (e.g. miR-519d and SNTB2). Moreover, the overall protein ubiquitination in atherosclerotic plaque was significantly increased. The proteasome activity was increased early but decreased in advanced atherosclerosis. Our study revealed many classic and novel genes and miRNAs involved in atherosclerosis and indicated the effects of ubiquitin-proteasome system on atherosclerosis might be closely related to the course of atherosclerosis. However, the efficacy of proteasome inhibitors in the treatment of atherosclerosis still needs more research.
The whole-genome landscape of Burkitt lymphoma subtypes
BLOOD
Authors: Panea, Razvan I.; Love, Cassandra L.; Shingleton, Jennifer R.; Reddy, Anupama; Bailey, Jeffrey A.; Moormann, Ann M.; Otieno, Juliana A.; Ong'echa, John Michael; Oduor, Cliff I.; Schroeder, Kristin M. S.; Masalu, Nestory; Chao, Nelson J.; Agajanian, Megan; Major, Michael B.; Fedoriw, Yuri; Richards, Kristy L.; Rymkiewicz, Grzegorz; Miles, Rodney R.; Alobeid, Bachir; Bhagat, Govind; Flowers, Christopher R.; Ondrejka, Sarah L.; Hsi, Eric D.; Choi, William W. L.; Au-Yeung, Rex K. H.; Hartmann, Wolfgang; Lenz, Georg; Meyerson, Howard; Lin, Yen-Yu; Zhuang, Yuan; Luftig, Micah A.; Waldrop, Alexander; Dave, Tushar; Thakkar, Devang; Sahay, Harshit; Li, Guojie; Palus, Brooke C.; Seshadri, Vidya; Kim, So Young; Gascoyne, Randy D.; Levy, Shawn; Mukhopadyay, Minerva; Dunson, David B.; Dave, Sandeep S.
Abstract
Burkitt lymphoma (BL) is an aggressive, MYC-driven lymphoma comprising 3 distinct clinical subtypes: sporadic BLs that occur worldwide, endemic BLs that occur predominantly in sub-Saharan Africa, and immunodeficiency-associated BLs that occur primarily in the setting of HIV. In this study, we comprehensively delineated the genomic basis of BL through whole-genome sequencing (WGS) of 101 tumors representing all 3 subtypes of BL to identify 72 driver genes. These data were additionally informed by CRISPR screens in BL cell lines to functionally annotate the role of oncogenic drivers. Nearly every driver gene was found to have both coding and non-coding mutations, highlighting the importance of WGS for identifying driver events. Our data implicate coding and non-coding mutations in IGLL5, BACH2, SIN3A, and DNMT1. Epstein-Barr virus (EBV) infection was associated with higher mutation load, with type 1 EBV showing a higher mutational burden than type 2 EBV. Although sporadic and immunodeficiency-associated BLs had similar genetic profiles, endemic BLs manifested more frequent mutations in BCL7A and BCL6 and fewer genetic alterations in DNMT1, SNTB2, and CTCF. Silencing mutations in ID3 were a common feature of all 3 subtypes of BL. In vitro, mass spectrometry-based proteomics demonstrated that the ID3 protein binds primarily to TCF3 and TCF4. In vivo knockout of ID3 potentiated the effects of MYC, leading to rapid tumorigenesis and tumor phenotypes consistent with those observed in the human disease.